ImmuPharma plc (LON:IMM – Get Free Report) shot up 18.3% during mid-day trading on Friday . The stock traded as high as GBX 4.50 ($0.06) and last traded at GBX 4.26 ($0.05). 26,333,650 shares changed hands during trading, an increase of 36% from the average session volume of 19,375,852 shares. The stock had previously closed at GBX 3.60 ($0.04).
ImmuPharma Price Performance
The stock’s 50 day moving average is GBX 1.75 and its 200-day moving average is GBX 1.73. The company has a market capitalization of £16.39 million, a P/E ratio of -393.60 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- What is a support level?
- Bloom Energy: Powering the Future With Decentralized Energy
- Are Penny Stocks a Good Fit for Your Portfolio?
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Conference Calls and Individual Investors
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
